Medical Technology

@xconomy.com 3 years ago

Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin

@xconomy.com 3 years ago

Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D

@xconomy.com 3 years ago

Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue

@xconomy.com 3 years ago

Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases

@xconomy.com 3 years ago

Two Days, Six IPOs, and $1B Raised for Biotech Research & More

@xconomy.com 3 years ago

Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later

@xconomy.com 4 years ago

Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses

@xconomy.com 4 years ago

Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More

@xconomy.com 4 years ago

Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More

@xconomy.com 4 years ago

Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer

@xconomy.com 4 years ago

Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers

@xconomy.com 4 years ago

Schrödinger Sets Course for IPO to Support Growing Internal Pipeline

@xconomy.com 4 years ago

Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic

@xconomy.com 4 years ago

Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds